Alcon (XSWX:ALCE) EPS without NRI: CHF2.54 (TTM As of Mar. 2026)


XSWX:ALCE Alcon Inc XSWX:ALCE
53 GF Score
Price CHF55.60
GF Value CHF73.46
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alcon EPS without NRI?

Alcon XSWX:ALCE +3.65% 53 EPS without NRI is CHF2.54 as of Mar. 2026. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 667 Medical Devices & Instruments companies, Alcon ranks worse than 53.67% on this metric.

Alcon's earnings per share without non-recurring items for the three months ended in Mar. 2026 was CHF0.67. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2.54.

During the past 12 months, Alcon's average earnings per share (NRI) Growth Rate was -3.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 5.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 18.50% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Alcon's EPS without NRI or its related term are showing as below:

XSWX:ALCE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.5   Med: 4.7   Max: 36.9
Current: 5.4

During the past 10 years, Alcon's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 36.90% per year. The lowest was -20.50% per year. And the median was 4.70% per year.

XSWX:ALCE's 3-Year EPS without NRI Growth Rate is ranked worse than
53.67% of 667 companies
in the Medical Devices & Instruments industry
Industry Median: 8.1 vs XSWX:ALCE: 5.40

Alcon's EPS (Diluted) for the three months ended in Mar. 2026 was CHF0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.33.

Alcon's EPS (Basic) for the three months ended in Mar. 2026 was CHF0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.33.


Alcon  (XSWX:ALCE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alcon EPS without NRI Related Terms


Alcon EPS without NRI Historical Data

* Premium members only.

The historical data trend for Alcon's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alcon EPS without NRI Chart

Alcon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.98 2.09 2.37 2.72 2.45

Alcon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.62 0.63 0.62 0.67

XSWX:ALCE vs ISRG, BDX, MDLN: EPS without NRI Comparison

For the Medical Instruments & Supplies subindustry, Alcon's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alcon PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Alcon's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Alcon's PE Ratio without NRI falls into.


XSWX:ALCE
53GF Score
Alcon Inc XSWX:ALCE
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alcon EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of CHF2.54 mean?
Alcon (XSWX:ALCE) has a EPS without NRI of CHF2.54 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alcon and its competitors. According to the industry distribution chart, Alcon ranks #358 out of 667 companies in the Medical Devices & Instruments industry, placing it in the top 53.7%.
Is Alcon's EPS without NRI too high?
Alcon's current EPS without NRI is CHF2.54. Based on the distribution chart, Alcon ranks #358 out of 667 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #358 out of 667 companies for EPS without NRI. This places Alcon in the lower half of its industry. The industry median EPS without NRI is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current EPS without NRI is CHF2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current EPS without NRI is CHF2.54. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current EPS without NRI is CHF2.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alcon (XSWX:ALCE) Overvalued in 2026?

Based on GuruFocus' analysis, Alcon stock appears to be undervalued. The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46. GuruFocus considers Alcon to be Modestly Undervalued.

Key valuation signals for XSWX:ALCE:

  • EPS without NRI: CHF2.54
  • GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alcon Business Description

Address Chemin de Blandonnet 8, Vernier, Geneva, CHE, 1214
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score

Get the complete analysis for XSWX:ALCE

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF55.60
Price
CHF73.46
GF Value